Educational analysis only — not financial advice. Always do your own due diligence.
ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Under an extreme stress test where the prevalent disease pipeline yields zero commercial value, ALNY reverts to a mature rare-disease biotech. This drops terminal multiples to 15x and compresses peak margins to 25%, resulting in our $387 bear caseBear caseThe worst-realistic outcome — what happens if our top three risks materialize together. Used to set the floor of our fair-value range and inform position sizing. floor.
Key prevalent indication readouts, such as hypertension or obesity, fail to show superiority, restricting TAM strictly to rare diseases.
IRA and competitive pressure limit peak operating margins below the projected 35%, trapping the firm in a lower-return profile.
CRISPR and base editing therapies permanently cure indications ALNY currently manages chronically, destroying chronic recurring revenue streams.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
